Alopecia Areata's Psychological Impact on Quality of Life, Mental Health, and Work Productivity: A Scoping Review

References (42)

1. 1 Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients [DOI]
2. 2 Hair follicle immune privilege and its collapse in alopecia areata [DOI]
3. 3 Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial [DOI]
4. 4 Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study [DOI]
5. 5 Alopecia areata and health-related quality of life: a systematic review and meta-analysis [DOI]
6. 6 Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review [DOI]
7. 7 The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata [DOI]
8. 8 JAK inhibitors for alopecia areata: a systematic review and meta‐analysis [DOI]
9. 9 Treatment of alopecia areata: An Australian expert consensus statement [DOI]
10. 10 Tofacitinib for the treatment of alopecia areata and variants in adolescents [DOI]
11. 11 Methotrexate for alopecia areata: A systematic review and meta-analysis [DOI]
12. 12 Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study [DOI]
13. 13 Development of the alopecia areata scale for clinical use: Results of an academic–industry collaborative effort [DOI]
14. 14 Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review [DOI]
15. 15 Nail changes in alopecia areata: an update and review [DOI]
16. 16 The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata [DOI]
17. 17 Minoxidil for patchy alopecia areata: systematic review and meta‐analysis [DOI]
18. 18 Predictors of QOL in Patients with Alopecia Areata [DOI]
19. 19 Psoriatic Alopecia/Alopecia Areata–Like Reactions Secondary to Anti–Tumor Necrosis Factor-α Therapy: A Novel Cause of Noncicatricial Alopecia [DOI]
20. 20 Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study [DOI]
21. 21 HrQoL in hair loss‐affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety [DOI]
22. 22 Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata – a large retrospective study on 142 patients with a self‐controlled design [DOI]
23. 23 Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia [DOI]
24. 24 Evaluation of serum zinc level in patients with newly diagnosed and resistant alopecia areata [DOI]
25. 25 Serum Vitamin D in patients with alopecia areata [DOI]
26. 26 Platelet-Rich Plasma and Its Utilities in Alopecia: A Systematic Review [DOI]
27. 27 Alopecia Areata After Vaccination: Recurrence with Rechallenge [DOI]
28. 28 Prognostic factors in methylprednisolone pulse therapy for alopecia areata [DOI]
29. 29 Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review [DOI]
30. 30 Alopecia areata: a review of disease pathogenesis [DOI]
31. 31 Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe.
32. 32 Retrospective review of diphencyprone in the treatment of alopecia areata [DOI]
33. 33 Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata [DOI]
34. 34 Five‐year experience in the treatment of alopecia areata with DPC [DOI]
35. 35 A review on laser and light-based therapies for alopecia areata [DOI]
36. 36 Sequential high‐ and low‐dose systemic corticosteroid therapy for severe childhood alopecia areata [DOI]
37. 37 Bimatoprost in dermatology [DOI]
38. 38 Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases [DOI]
39. 39 Concentric polycyclic regrowth pattern in alopecia areata [DOI]
40. 40 Efficacy of superficial cryotherapy on the eyebrows of patients with alopecia universalis also treated with contact immunotherapy on the scalp: a prospective, split‐face comparative study [DOI]
41. 41 Treatment for facial alopecia areata: A systematic review with evidence-based analysis [DOI]
42. 42 Five-year experience in the treatment of alopecia areata with DPC [DOI]

Cited by 8

Showing 2 of 8 known citations — external sources report more than can currently be individually listed.

Related research

• Assessment of Anxiety in Healthcare Providers Working in ICU during COVID-19 Pandemics — shares topic coverage
• The COVID-19 Pandemic and Its Effect on the Mental Health of Doctors in India — shares topic coverage
• Prevalence and Comorbidity of Depression and Anxiety among Medical Students in Babcock University, Ogun State, Nigeria — shares topic coverage
• Psychological Wellbeing of Healthcare Workers in Different Hospitals of Karachi (Pakistan) During COVID-19 Pandemic — shares topic coverage
• Covid-19 Psychological Trauma and its Associated Factors among Nurses in Southwest Nigeria — shares topic coverage